Degeneration clinical trials

Explore recruiting degeneration clinical trials.

Recruiting degeneration studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Degeneration trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients with Stargardt’s Macular Degeneration

France

Therapeutic exploratory (Phase II) EU CTIS Study details

An open-label study to determine the long-term safety, tolerability and biological activity of SAR421869 in patients with Usher syndrome Type 1B

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)

France, Belgium

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Aflibercept 8mg for high-frequent Faricimab and prior Aflibercept 2mg treated Neovascular age-related macular degeneration: a monocenter, single-arm, open-label extension study (A-FAN)

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

Faricimab for high-frequent Aflibercept treated Neovascular age-related macular degeneration: a monocenter, randomized, double-masked comparator-controlled study (FAN study)

Austria

Phase III and phase IV (Integrated) EU CTIS Study details

Degeneration trials by city

Degeneration in Toronto Degeneration in Vancouver Degeneration in Montreal Degeneration in Calgary Degeneration in Edmonton Degeneration in Ottawa Degeneration in Winnipeg Degeneration in Quebec City Degeneration in Hamilton Degeneration in Kitchener Degeneration in London Degeneration in Halifax Degeneration in New York Degeneration in Los Angeles Degeneration in Chicago Degeneration in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease